SE445295B - Digoxin-innehallande tablett - Google Patents

Digoxin-innehallande tablett

Info

Publication number: SE445295B
Authority: SE; Sweden
Prior art keywords: digoxin; tablet; silicic acid; active substance; tablets
Prior art date: 1978-10-18

Application number

SE7907527A

Other languages

English (en)

Swedish (sv)

Other versions

SE7907527L (sv

Inventor

B Asmussen

G A Ulex

Original Assignee

Beiersdorf Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-10-18

Filing date

1979-09-11

Publication date

1986-06-16

1979-09-11 Application filed by Beiersdorf Ag filed Critical Beiersdorf Ag

1980-04-19 Publication of SE7907527L publication Critical patent/SE7907527L/xx

1986-06-16 Publication of SE445295B publication Critical patent/SE445295B/sv

Links

LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 33
229960005156 digoxin Drugs 0.000 claims description 33
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 33
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 33
239000013543 active substance Substances 0.000 claims description 24
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 22
235000012239 silicon dioxide Nutrition 0.000 claims description 22
239000011164 primary particle Substances 0.000 claims description 5
239000011148 porous material Substances 0.000 claims description 4
239000000470 constituent Substances 0.000 claims description 2
210000001035 gastrointestinal tract Anatomy 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 12
238000000034 method Methods 0.000 description 11
238000012423 maintenance Methods 0.000 description 9
230000036470 plasma concentration Effects 0.000 description 9
239000000243 solution Substances 0.000 description 8
239000000203 mixture Substances 0.000 description 6
239000007916 tablet composition Substances 0.000 description 6
238000004090 dissolution Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
238000001035 drying Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
235000011389 fruit/vegetable juice Nutrition 0.000 description 3
239000008187 granular material Substances 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000037406 food intake Effects 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
229930182470 glycoside Natural products 0.000 description 2
150000002338 glycosides Chemical class 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
239000003232 water-soluble binding agent Substances 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
239000004115 Sodium Silicate Substances 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
229940097217 cardiac glycoside Drugs 0.000 description 1
239000002368 cardiac glycoside Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000002360 explosive Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001595 flow curve Methods 0.000 description 1
239000003292 glue Substances 0.000 description 1
XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
238000004080 punching Methods 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
239000013074 reference sample Substances 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
229910052911 sodium silicate Inorganic materials 0.000 description 1
239000006104 solid solution Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
229930002534 steroid glycoside Natural products 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

SE7907527A 1978-10-18 1979-09-11 Digoxin-innehallande tablett SE445295B (sv)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE2845326A DE2845326C2 (de)	1978-10-18	1978-10-18	Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung

Publications (2)

Publication Number	Publication Date
SE7907527L SE7907527L (sv)	1980-04-19
SE445295B true SE445295B (sv)	1986-06-16

Family

ID=6052475

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE7907527A SE445295B (sv)	1978-10-18	1979-09-11	Digoxin-innehallande tablett

Country Status (14)

Country	Link
US (1)	US4254099A (de)
JP (1)	JPS5555113A (de)
AT (1)	AT371712B (de)
AU (1)	AU523794B2 (de)
BE (1)	BE879487A (de)
CA (1)	CA1125656A (de)
CH (1)	CH640738A5 (de)
DE (1)	DE2845326C2 (de)
ES (1)	ES485399A0 (de)
FR (1)	FR2439018A1 (de)
GB (1)	GB2033225B (de)
NL (1)	NL7907244A (de)
SE (1)	SE445295B (de)
ZA (1)	ZA795530B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1146866A (en) *	1979-07-05	1983-05-24	Yamanouchi Pharmaceutical Co. Ltd.	Process for the production of sustained release pharmaceutical composition of solid medical material
JPS56152416A (en) *	1980-04-25	1981-11-26	Tsumura Juntendo Inc	Preparation of chinese herbal remedy tablet
EP0080673B1 (de) *	1981-11-28	1985-05-29	Roche Diagnostics GmbH	Oral applizierte Zubereitungsformen von Guar-Mehl
US4581232A (en) *	1983-07-20	1986-04-08	Warner-Lambert Company	Magnesium trisilicate suitable for preparation of medicament adsorbates
GB8413191D0 (en) *	1984-05-23	1984-06-27	Beecham Group Plc	Pharmaceutical composition
US4617294A (en) *	1985-04-22	1986-10-14	Ppg Industries, Inc.	Animal feed supplement
US5310572A (en) *	1987-02-03	1994-05-10	Dow Corning Corporation	Process for forming a coated active agent-containing article
IT1216570B (it) *	1988-04-08	1990-03-08	Vectorpharma Int	Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
US5039699A (en) *	1989-03-27	1991-08-13	Lederle (Japan), Ltd.	Anti-peptic ulcer agent
JPH03109332A (ja) *	1989-09-21	1991-05-09	Shiseido Co Ltd	薬剤組成物
GB9025251D0 (en) *	1990-11-20	1991-01-02	Solomon Montague C	Nifedipine dosage forms
US5629016A (en) *	1991-01-30	1997-05-13	Glaxo Wellcome Inc.	Water-dispersible tablets
MY110880A (en) *	1991-01-30	1999-06-30	The Wellcome Foundation Ltd	Water-dispersible tablets
US5698226A (en) *	1993-07-13	1997-12-16	Glaxo Wellcome Inc.	Water-dispersible tablets
JP4064476B2 (ja) *	1996-03-29	2008-03-19	エラワンファーマスーティカルリサーチアンドラボラトリーカンパニーリミテッド	二酸化珪素を有する球状凝集した澱粉
GB9720061D0 (en) *	1997-09-19	1997-11-19	Crosfield Joseph & Sons	Metal compounds as phosphate binders
CA2311734C (en) *	2000-04-12	2011-03-08	Bristol-Myers Squibb Company	Flash-melt oral dosage formulation
JP2004531537A (ja) *	2001-05-01	2004-10-14	ファイザー・プロダクツ・インク	一様な薬剤分布と効力を有する低用量製薬組成物の製造方法
TWI324074B (en) *	2001-10-09	2010-05-01	Bristol Myers Squibb Co	Flashmelt oral dosage formulation
MY142989A (en) *	2004-03-10	2011-02-14	Bayer Schering Pharma Ag	Stabilised supersaturated solids of lipophilic drugs
CA2615063A1 (en) *	2005-07-22	2007-02-01	Myriad Genetics, Inc.	High drug load formulations and dosage forms
MY157620A (en)	2006-01-31	2016-06-30	Cytochroma Dev Inc	A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
MX2009008935A (es)	2007-02-23	2009-11-02	Gilead Sciences Inc	Moduladores de las propiedades farmacocineticas de productos terapeuticos.
GB0714670D0 (en) *	2007-07-27	2007-09-05	Ineos Healthcare Ltd	Use
GB0720220D0 (en) *	2007-10-16	2007-11-28	Ineos Healthcare Ltd	Compound
MX2010011963A (es)	2008-05-02	2010-12-06	Gilead Sciences Inc	Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
GB0913525D0 (en)	2009-08-03	2009-09-16	Ineos Healthcare Ltd	Method
GB201001779D0 (en)	2010-02-04	2010-03-24	Ineos Healthcare Ltd	Composition
CN113842362A (zh) *	2012-11-14	2021-12-28	格雷斯公司	含有生物活性材料与无序无机氧化物的组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR541197A (fr) *	1920-01-08	1922-07-24	Lilly Co Eli	Procédé d'enrobage de remèdes et en particulier d'alcaloîdes d'ipéca de manière à ce qu'ils puissent être administrés par la bouche et absorbés par l'intestin
US2038694A (en) *	1930-10-15	1936-04-28	Davision Chemical Corp	Medicament
US2698822A (en) *	1951-04-28	1955-01-04	Fougera & Co Inc E	Cardiac glycoside buccal composition
US2820741A (en) *	1954-04-29	1958-01-21	Abbott Lab	Aluminum aspirin granulation and method for making
US2857313A (en) *	1956-03-27	1958-10-21	Ciba Pharm Prod Inc	Self-lubricating granulation
US3034911A (en) *	1959-03-25	1962-05-15	Nat Starch Chem Corp	Tablet disintegrants
NL271458A (de) *	1960-11-17
US3148124A (en) *	1962-06-12	1964-09-08	William E Gaunt	Method of preparing sustained release pharmaceutical tablets
DE1228029C2 (de) *	1964-05-09	1973-05-17	Merck Ag E	Verfahren zur Herstellung von Tabletten durch Pressen von Pulvergemischen ohne vorhergehende Granulation
US3400197A (en) *	1965-01-26	1968-09-03	Robins Co Inc A H	Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
DE1492034A1 (de) *	1965-05-18	1969-02-20	Merck Ag E	Verfahren zur Herstellung fester haltbarer Zubereitungen von empfindlichen,in Wasser schwer loeslichen Wirkstoffen,vorzugsweise Arzneimitteln
NL6906980A (de) *	1968-05-22	1969-11-25
US3696091A (en) *	1970-06-03	1972-10-03	Boehringer Sohn Ingelheim	Novel cardiac-active principles of the cardenolide glycoside class
US3632778A (en) *	1970-06-10	1972-01-04	Hoffmann La Roche	Tablets containing l-dopa
US3725556A (en) *	1970-11-12	1973-04-03	D Hanssen	Method of manufacturing rapidly disintegrating pharmaceutical tablets
US3908003A (en) *	1971-07-02	1975-09-23	American Home Prod	Enrobed solid hydrophobic tableting lubricants and compositions
US3923969A (en) *	1973-06-12	1975-12-02	Battelle Institut E V	Carrier system for a drug with sustained release
US3929996A (en) *	1973-06-29	1975-12-30	Interx Research Corp	Pharmaceutical compositions containing a digoxin complex
US3884905A (en) *	1974-05-02	1975-05-20	Interx Research Corp	Pro-drug forms of digoxin
US3946110A (en) *	1974-05-30	1976-03-23	Peter, Strong Research And Development Company, Inc.	Medicinal compositions and methods of preparing the same
US4151273A (en) *	1974-10-31	1979-04-24	The Regents Of The University Of California	Increasing the absorption rate of insoluble drugs
US4013785A (en) *	1975-03-21	1977-03-22	Bristol-Myers Company	Apap tablet containing fumed silica and process for manufacturing same
US4143129A (en) *	1975-10-11	1979-03-06	Lilly Industries Limited	Cephalexin tablets
US4021546A (en) *	1976-03-08	1977-05-03	Interx Research Corporation	Pro-drug forms of digoxin and method of preparing and using same
US4202888A (en) *	1976-07-12	1980-05-13	Kali-Chemie Pharma Gmbh.	Readily enterally absorbable pharmaceutical compositions of cardiac glycosides and preparation thereof
US4147768A (en) *	1976-09-13	1979-04-03	Interx Research Corporation	Enteric coated digoxin and therapeutic use thereof

1978
- 1978-10-18 DE DE2845326A patent/DE2845326C2/de not_active Expired
1979
- 1979-08-31 CH CH791679A patent/CH640738A5/de not_active IP Right Cessation
- 1979-09-11 SE SE7907527A patent/SE445295B/sv unknown
- 1979-09-28 NL NL7907244A patent/NL7907244A/nl not_active Application Discontinuation
- 1979-10-01 US US06/080,900 patent/US4254099A/en not_active Expired - Lifetime
- 1979-10-15 AU AU51789/79A patent/AU523794B2/en not_active Ceased
- 1979-10-16 JP JP13250879A patent/JPS5555113A/ja active Pending
- 1979-10-17 FR FR7925763A patent/FR2439018A1/fr active Granted
- 1979-10-17 ZA ZA00795530A patent/ZA795530B/xx unknown
- 1979-10-17 ES ES485399A patent/ES485399A0/es active Granted
- 1979-10-17 GB GB7936001A patent/GB2033225B/en not_active Expired
- 1979-10-17 AT AT0675979A patent/AT371712B/de not_active IP Right Cessation
- 1979-10-17 CA CA337,779A patent/CA1125656A/en not_active Expired
- 1979-10-18 BE BE0/197703A patent/BE879487A/fr not_active IP Right Cessation

Also Published As

Publication number	Publication date
ATA675979A (de)	1982-12-15
FR2439018A1 (fr)	1980-05-16
GB2033225B (en)	1983-06-15
DE2845326A1 (de)	1980-04-24
AU523794B2 (en)	1982-08-12
US4254099A (en)	1981-03-03
CH640738A5 (de)	1984-01-31
AU5178979A (en)	1980-04-24
NL7907244A (nl)	1980-04-22
DE2845326C2 (de)	1985-05-23
ES8100077A1 (es)	1980-11-01
GB2033225A (en)	1980-05-21
CA1125656A (en)	1982-06-15
JPS5555113A (en)	1980-04-22
BE879487A (fr)	1980-02-15
ES485399A0 (es)	1980-11-01
FR2439018B1 (de)	1983-03-04
SE7907527L (sv)	1980-04-19
ZA795530B (en)	1980-09-24
AT371712B (de)	1983-07-25

Publication	Publication Date	Title
SE445295B (sv)	1986-06-16	Digoxin-innehallande tablett
AU603870B2 (en)	1990-11-29	Pharmaceutical composition, pharmaceutical granulate and process for their preparation
DK175138B1 (da)	2004-06-14	Fast dihydrocodeinpræparat med reguleret afgivelse
CA2134196C (en)	2004-02-10	Pharmaceutical preparation and process for its manufacture
KR101283820B1 (ko)	2013-07-15	인 화합물의 흡수를 위한 경구용 조성물
US11786506B2 (en)	2023-10-17	Transmucosal psychoactive alkaloid composition and preparation thereof
CN112370436B (zh)	2022-04-29	一种预防或治疗脑缺血再灌注损伤纳米药物及其制备方法与应用
EP0231826A2 (de)	1987-08-12	Theophyllintablette mit verzögerter Freigabe
CN101378767A (zh)	2009-03-04	稳定的碳酸镧组合物
CN102470183A (zh)	2012-05-23	一种含二甲硅油/西甲硅油的药物组合物
CN114796133A (zh)	2022-07-29	一种注射用药物制剂及其制备方法
CN105983098B (zh)	2020-02-21	用于提高难溶性的抗肿瘤药物生物利用度的固体组合物及其制备方法
Reddy et al.	2010	Development and in vitro evaluation of glibenclamide Aloe barbadensis miller leaves mucilage controlled release matrix tablets
JP2008536922A (ja)	2008-09-11	オランザピンの医薬用経口崩壊錠
JPH11158066A (ja)	1999-06-15	イブプロフェン含有医薬製剤
JP2638156B2 (ja)	1997-08-06	薬剤組成物
Prasad Panda et al.	2015	Extraction and performance evaluation of Salvia hispanica mucilage as natural disintegrants for optimization of pyrilamine maleate fast dissolving tablets
CN111386104B (zh)	2022-09-02	一种用于抗病毒感染的药物组合物及制备方法
CN100409857C (zh)	2008-08-13	一种用于抗骨质疏松的中药制剂
GB2170403A (en)	1986-08-06	Anti-asthmatic composition and preparation thereof
JPH04368330A (ja)	1992-12-21	ペミロラストカリウムの徐放性製剤
CN113599375B (zh)	2023-08-18	一种治疗口腔疾病的经口给药药物及用途
EP0005733A1 (de)	1979-12-12	Pharmazeutische Zusammensetzungen zur Anwendung bei der Behandlung diabetischer Nephropathie und Verfahren zu deren Herstellung
WO2014186851A1 (pt)	2014-11-27	Microencapsulados de própolis vermelha, processo de obtenção de microencapsulados, composições farmacêuticas contendo os mesmo, processo de obtenção de composições farmacêuticas e usos
CA1176984A (en)	1984-10-30	Pharmaceutical compositions for the treatment of gastric hyperacidity, gastritis and gastroduodenal ulcers